Provided by Tiger Fintech (Singapore) Pte. Ltd.

Helius Medical Technologies, Inc.

1.09
-0.0500-4.39%
Post-market: 1.100.0100+0.92%18:06 EDT
Volume:15.40M
Turnover:22.33M
Market Cap:575.59K
PE:-0.02
High:1.43
Open:1.39
Low:1.05
Close:1.14
Loading ...

Top Midday Decliners

MT Newswires Live
·
Yesterday

Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering

THOMSON REUTERS
·
05 Jun

Press Release: Helius Medical Technologies Announces Pricing of $9.1 Million Public Offering

Dow Jones
·
05 Jun

Helius Medical compliant with Nasdaq bid price rule listing criteria

TIPRANKS
·
04 Jun

Helius Medical Technologies, Inc. Compliant With Nasdaq Bid Price Rule Listing Criteria

THOMSON REUTERS
·
04 Jun

Helius Medical files to sell 3.45M shares of common stock

TIPRANKS
·
24 May

Helius Medical Technologies Inc. Conducted Special Stockholder Meeting

Reuters
·
24 May

Helius to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy® at CMSC Annual Meeting

GlobeNewswire
·
20 May

BRIEF-Helius Medical Technologies Announces Reverse Stock Split

Reuters
·
30 Apr

Helius Medical announces 1-for-15 reverse stock split

TIPRANKS
·
30 Apr

Helius Medical Technologies Announces Reverse Stock Split

THOMSON REUTERS
·
30 Apr

Helius Medical Technologies Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
26 Mar

Helius Medical Technologies Inc expected to post a loss of 94 cents a share - Earnings Preview

Reuters
·
24 Mar

Helius Medical Technologies, Inc. Announces the Establishment of a Wholly Owned Brain Computer Interface (“BCI”) Technology Private Subsidiary

THOMSON REUTERS
·
13 Mar

Helius Medical Technologies, Inc. Announces First Reimbursement by A Major Healthcare Provider for its Portable Neuromodulation Stimulator (PoNS®) Device

GlobeNewswire
·
11 Mar

BRIEF-Helius Medical Technologies Inc - Continues Non-Compliance With Nasdaq Minimum Bid Price Requirement

Reuters
·
08 Feb

Helius Medical Technologies Inc - Continues Non-Compliance With Nasdaq Minimum Bid Price Requirement

THOMSON REUTERS
·
08 Feb

Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-Term Therapeutic Effects of Pons Therapy® on Gait Deficit Improvement in Multiple Sclerosis From the Pons® Therapeutic Experience Program Study

THOMSON REUTERS
·
22 Jan

Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-term Therapeutic Effects of PoNS Therapy® on Gait Deficit Improvement in Multiple Sclerosis from the PoNS® Therapeutic Experience Program Study

GlobeNewswire
·
22 Jan

Helius Medical Technologies, Inc. Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $3.7 Million Gross Proceeds Priced at-the-Market

THOMSON REUTERS
·
22 Jan